Incyte (INCY) Other Non-Current Assets (2010 - 2026)
Incyte (INCY) reported Other Non-Current Assets of $1.8 million for Q1 2026, up 10.27% on a YoY basis from $1.7 million in Q1 2025, and down 89.89% quarter-over-quarter from $18.2 million in Q4 2025.
Incyte (INCY) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Incyte has reported Other Non-Current Assets for 16 years, with the latest figure at $1.8 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 10.27% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (up 10.27% YoY), and the FY2025 full-year result was $18.2 million, up 1019.98% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.8 million, down from $18.2 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $81.0 million in Q3 2023, with the low at $1.6 million in Q4 2024.
- Historically, Other Non-Current Assets has averaged $17.5 million across 5 years, with a median of $1.8 million in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 95.45% — and 2025, when it soared 1895.83%.
- Incyte's Other Non-Current Assets stood at $1.7 million in 2022, then grew by 8.66% to $1.8 million in 2023, then dropped by 12.09% to $1.6 million in 2024, then jumped by 1019.98% to $18.2 million in 2025, then plunged by 89.89% to $1.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.8 million (Q1 2026), $18.2 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.84 Mn |
| Dec 31, 2025 | 18.17 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 32.55 Mn |
| Mar 31, 2025 | 1.67 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 40.38 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.63 Mn |
| Dec 31, 2023 | 1.85 Mn |
| Sep 30, 2023 | 80.96 Mn |
| Jun 30, 2023 | 31.71 Mn |
| Mar 31, 2023 | 1.72 Mn |
| Dec 31, 2022 | 1.70 Mn |
| Sep 30, 2022 | 23.67 Mn |
| Jun 30, 2022 | 23.01 Mn |
| Mar 31, 2022 | 31.42 Mn |
| Dec 31, 2021 | 37.30 Mn |
| Sep 30, 2021 | 24.79 Mn |
| Jun 30, 2021 | 20.45 Mn |